IP Indian Journal of Neurosciences 2023;9(1):1–7

Content available at: https://www.ipinnovative.com/open-access-journals

IP Indian Journal of Neurosciences

Journal homepage: https://www.ijnonline.org/

Review Article

# Management of motor neuron disease with updated therapies: A review

**Gautam Kumar[1], Ravi Kumar[2,*], Kuldeep Saini[2], Sunita Jha[2]**

[1]*Shri Ram Group of Colleges, Muzaffarnagar, Uttar Pradesh, India*
[2]*S.D. College of Pharmacy and Vocational Studies, Muzaffarnagar, Uttar Pradesh, India*

ARTICLE INFO

*Article history:*
Received 03-03-2023
Accepted 27-03-2023
Available online 25-04-2023

*Keywords:*
Motor neuron illness
ALS (Amyotrophic lateral sclerosis)
PMA (Progressive muscular atrophy)
Respiratory muscles failure & PLS (Primary lateral sclerosis)

ABSTRACT

Motor neuron disorder is a neurodegenerative disorder that causes weakness, respiratory muscle and also bulbar and respiratory failure cause death. Generally motor neuron disorder is sporadic but in some cases roughly 10 is got inherited. According to current studies the new motor neuron disorder genes are found. Pathologically motor neuron disorder & clinically miscellaneous, neuroprotective and remedial targets have been delicate to identified. According to these studies, in motor neuron disorder the evolution growth are similar as bettered understanding of the colorful clinical phenotypes, the boundlessness together the frntotemporal madness, part of genetics, development of standard of care and the global clinical trialspipelines. The vestige of riluzole medicine only disorder modification drug which utilized for the disorder treatment. These drugs have power to improve the cycle of living. In the operation of motor neuron disorder the intensive treatment are important which can be multifunctional. And noninvasive respiratory therapy that involves the delivery of air or a mixture of oxygen combined with other gases by positive pressure into the lungs which can improves the chances of living in MND cases in case of disturbance of exhalation and inhalation. Motor neuron disorder is found further generally in males than females. Motor neuron disease is shown the dropping of neuron in the kidney, spinal cord and mind which show by both up and down motor neuron symptoms & signs they affect arms, bulbar & respiration.



## 1. Introduction

Motor neuron sickness are neurodegenerative illness (disease) which mostly found under adult patients which causes the bulbar defect, respiration defect and also arms defect. Generally the patients get dying after about 4-6 year that cause respiration disturbance, who's suffering from motor neuron illness.[1] Motor neuron disorders are neurodegenerative and longish disorder which show effects generally efferent neurons. The motor neuron disorders are very dangerous for living and produced a character that plays essential opinion give thought to understand, produce and interpret. These are also essential but absolutely not above to diagnose of reversible mimic and treatment of motor neuron disorder. The disorder generally shows effects substantially in intermediate periods and senior person whose already got the age about 50 times and above but youngish people are also suffers. MND are domestic about 10 cases but 90 are sporadic. The complaint causes cell death and cell injury of lower efferent nerves under kidney. And whose people which suffering from this illness generally produced the composition of up and down efferent neuron that indicates escorted by wasting generally accompanied by pathological brisk revulsion and progressive muscle weakness, ultimately also involving bulbar muscle and branch.[2] Inside the motor neuron disorder the descent is not present; here the unknown causes of ALS. Nonetheless, they include

* *Corresponding author*.
*E-mail address*: ravikashyap7417@gmail.com (R. Kumar).

https://doi.org/10.18231/j.ijn.2023.001

of several threat elements are proposed. And in this also comprise metals, radiation field, physical exertion, contagions, chemicals, fungi, bacteria, prions, cell organ connected ecology, acetylcholine neuron inflammation, protein related abnormalities, advanced power spending otherwise input and continuing disability of microtubules, sugar biotransformation, intermediate poverties in neuronal transfer, autoimmunity, reaction of physical composition inside the astroglia, microglia & low to high disturbing mind wound.[3–5] In western populations, the incidence of motor neuron disease including Australia is about 2-3/100000 and with a national prevalence of about 8/100000.[6] Currently, approximately 1500 Australian patients which suffer from the motor neuron disease.[7] And remains no test for motor neuron disease, diagnosis through clinical findings and it is supported by investigation such as structural imaging and neuropsychological testing for exclude mimic disorder.[8] As clinically given that the motor neuron disease & habitual miscellaneous, neuroprotective & remedial select that delicate to linked. Still, the recent times the developments have been restoring innovate research into this devastating disorder.

### *1.1. Signs and symptoms of respiratory insufficiency in motor neuron disease symptoms*

#### *1.1.1. Symptoms*

1. Nocturia
2. Morning headache
3. Orthopnoea
4. Dyspnoea on talking or exertion
5. Excessive daytime sleepiness
6. Anxiety
7. COPD
8. Anorexia
9. Tiredness
10. Sadness
11. Absent mindedness

#### *1.1.2. Indication*

1. Use of accessory muscle
2. Sweating
3. Tachycardia
4. Confusion
5. Increased respiratory rate
6. Double breathing
7. Coughing
8. Papilloedema
9. Slimming
10. Decreased chest movement

## 2. Causes

Motor neuron disorder causes is unknown. According to recent study has committed on all sides of the earth and the developing harmful effects of motor neuron illness hasn't come out the high flown by event, life spend time and food. Motor neuron disease hasn't found in pandemics, this isn't materialize arise through other disorders and isn't contagious. Substantially it occurs inside males than females. Several persons have knowledge that the indication show suddenly after the 40 years and between 50-70 years progressed of people is common in motor neuron disease. Although rare, here found some inheritable elements for some people & these inheritable elements by yours parentage to increase the threat of produced motor neuron disease.[9]

### *2.1. Classification of motor neuron disease*

Generally motor neuron complaints classified are:[10]

1. ALS (Amyotrophic lateral sclerosis): Amyotrophic lateral sclerosis are through a long way the bulk usually & that cause decrease the down efferent neurons (LMN) & upper motor neuron (UMN) which produce a characteristic mixed picture.[10] Common symptoms are includes such as muscles weakness, cramping & shuddering which leads to ultimately to power disability. Mostly inside the phase, in the patient indication are produced like dysphagia & dyspnea. Substantially patient death in case of respiration system fails.[11]
2. PMA (Progressive muscular atrophy)**:** Progressive muscular atrophy are disorder which found generally of the lower motor neuron in spite of the fact that which dead in disorder, not many upper motor neuron signs can be produced. Progressive muscular atrophy is essential for deterioration the bottom efferent neuron of spine inside is not present the bulbar features & superior efferent neuron. Formerly again, like definite reality through amyotrophic lateral sclerosis variation about motor neuron disease are contestation accompanied by cons ider rationality of progressive muscular atrophy. And some have reported veritably sluggishly progressive course for progressive muscular atrophy, but this is not always the case in one that can be as long as 20-30 years.[12,13]
3. PLS (Primary lateral sclerosis)**:** Primary lateral sclerosis is very rare formation of motor neuron disease. These are generally includes upper motor neuron which accompanied by the stylish prognostic. Not large quantity of lower motor neuron elements can be ultimately produced. Unsurprisingly, efferent nerves survive inside the large-optical strength & genital bottom is spare inside the every formation about motor neuron disease. Defense favorers of genotypic variations are through the domestic of amyotrophic lateral sclerosis. Now in domestic formation of amyotrophic lateral sclerosis is a primary lateral

sclerosis genotype are completely explained.[14]

## 3. Pathophysiology of MND

Efferent nerves disorder is characterized through the picky deformation of efferent nerves and also involves cone-shaped fibrous inside brain, head efferent nerves and motor neuron inside frontal cornucopia cells. Roughly 90% of cases are sporadic in motor neuron complaint, there being no given family history and cause. And about 10% patients are domestic. The definition also through the useful analyzed for knowing association inheritable changes and a family history. Inside roughly 20% individuals escorted by inheritable formation about ALS, the amyotrophic lateral sclerosis mutation has been found.[15] A substance has revolutionary antioxidant properties which reduced disturbance in the balance between the production of reactive oxygen species and antioxidant defenses present in all forms, ALS is encrypt to adjuvant SOD (superoxide dismutase). Substantially variant of motor neuron disease are SOD1 that causes suffering peoples demonstration substantiation of both corticospinal tract dysfunction & anterior cornucopia cell. PMA are a variation inside low efferent nerves included. These are less found into the male's persons who have better prognostic & an earlier mean age of onset otherwise amyotrophic lateral sclerosis. And other variations of motor neuron disease are also PLS (primary lateral scleroses) at most up efferent nerves deformation. Progressive muscular atrophy & Primary lateral sclerosis regard about 2 and 4 percent of motor neuron disease patients, independently,[16] however numerous of these cases promotes to amyotrophic lateral sclerosis above period.[17]

### *3.1. Oxidative stress*

Generally the effect of oxidative stress like as neurons may be injury and cumulative through free radical species within non-replicating cells. It is a major cause of the age related deterioration in neuron function which occurs in several neurodegenerative diseases. In the role of oxidative stress in motor neuron disease, there is particularly keen interest which gives the changes inside genetic for Zn/russet SOD enzymes uphold not more patients of domestic disorders. According to mortal posthumous towel studies by brain which indicates not absent of biological change for DNA & proteins which represented "vestiges" about liberated kills & in case of motor neuron disease as compared with controls, the changes are more pronounced.[18,19] And other posthumous neurological exchanges which include the change declaration of factors of the free radical scavengers into the cell defense system has break up during the course of motor neuron disease for show a tried discretionary feedback for not absence about strain.[20] Fibroblasts dressed which attained from the dermis of suffering peoples along both sporadic & domestic efferent neuron disorder which leads to increase perceptivity to free radical cuts as comparison along whose by dominance.[21]

### *3.2. Sleep disorder in motor neuron disease*

Sleep disorder breathing has been reported in 17-76% of patients with motor neuron disease.[22] It beget substantially difficulty in respiration, as well as lower part of respiratory system weak, are firstly useful medium to sleep disorder breathing inside the motor neuron disease. Sleep disorder breathing happens beforehand into track of motor neuron disease & habitual respiratory failure & precedes day symptoms.[23] At the opinion time of sleep disorder breathing, those cases which suffering from motor neuron disease frequently has normal respiratory muscle strength.[24–26] However, till here mixed motor/sensory nerves which originated from the C3-C5 spinal nerves in the neck includes along midsection (diaphragm) palsy if the severity of sleep disorder breathing is usually not significant.[27,28]

### *3.3. Predicting labels*

Many types of less forecast elements to exist into the motor neuron disease condition which have linked on disorder demonstration, larger lifetime. In small term meantime in the middle of diagnosis and clearly reduction of breathing power, pronounced weight loss, neurogenic disorder pronounced muscle weakness.[29] Here give a recommendation for especially motor neuron disease which can become not more hostile above period escorted by batch details slower disease progression in contemporary and a slightly dragged survival as compared with literal cases.[30,31] According to recent studies, these exchanges were unconventional about possibly disorder to outgrowth-modification treatments like that Riluzole medicine (medicine presently certified to treatment of motor neuron disease), percutaneous gastrostomy and non-invasive ventilation.[30]

### *3.4. Excitotoxicity*

It is the process in which neuron degenerate from excessive stimulation by neurotransmitter like as glutamate due to over activation of NMDA or AMPA receptors.[32] Glutamic acids are the essential compounds which play a vital role in exchanges of neurons in the brain. Removal of glutamate from the synaptic cleft is terminated of excitatory signal through protein transfer; these are present in pre-synaptic cleft cells. Inordinate encourage of neurological glutamic acid receptor can cause kill & damage it's cell through mechanism involve disorder of inner part of cell $ca^{++}$ level maintained and free revolutionaries product[33].

According to recent studies, crucial found especially function & expression of solute carrier family 1 member

2 (SLC1A2) and glutamate transporter 1(GLT-1), larger glutamic acid transferred of protein, which can bloodied in motor neuron disorder & in some case with this disease the glutamate concentration may be abnormal in cerebrospinal fluid and extracellular fluid [9.10]. According to this studies due to specifically disfigurement about ribonucleic acid process are essential etiology elements in disorder & not absence about unusual splicing ribonucleic acid transcript to SLC1A2 and GLT-1 has no covered into the patient which suffering from motor neuron disease[34]. However, also gives ideas especially the alternately splicing ribonucleic acid transcript can established into brain.[35]

## 4. Nutrition in MND

Weight loss and nutritional status are predictors of survival.[36–38] In substantially patients, malnourishment is relation to drop calories input & in less cases together respiration problems can hyperactive metabolic condition.[39,40] In motor neuron disease the frequency about malnourishment are unknown, yet differ between phases & instantiation of the disorder. According to recent studies, suggestion that 21% about divisional representative of cases was glutted from somatotypes, these have essential paresis which includes is whether or not.[41] In some cases which suffering from motor neuron disease develops weight gain which may be problematic? Those patients have prenominal limb fault confining his motility missing input of confining calories[42]. Difficulty in swallowing should be nearly covered and it's a complex phenomenon. It comprised lingual and labial dysfunction, pharyngeal weakness, reduction in laryngeal elevation, palatal incapacity, difficulty driving the swallowing kickback & cricopharyngeal hyperactive tonus. The efficacy and swallowing safety must be daily routine estimated by aware reports proceeds. The consuming food, drink and other substance are essential fragment to evaluate in diagnosis of patients. Clinically diagnoses are supplementation by investigation like visual fibres and videotape fluoroscopy examination. During swallowing to cover the oxygen desaturation the palpitation oximetry can be used. Nape auscultation can assist to detection desire and especially sounded desires and video fluoroscopy may be defect this, if this is suspected. The carer and knowledge about persons are essential for ensuring the sufficient nourishment is balanced through disorder. In motor neuron disease the consuming food, drinking and other substance are no source to decrease weight. And the patient along suffering from motor neuron disease often feels awkward eating in company.

### *4.1. Medical care*

#### *4.1.1. Clinically trials*

Moral clinical trials-several remedial agents has analyzed into clinically practice inside the cases among with efferent neuron disorder. Riluzole has several other potentially neuroprotective goods & it is a sodium channel blocker that inhibits the release of glutamate. It has also dragging survival potency produced by modification.[43] Here no better potential trial about anti-oxidant composites into the efferent neuron disorder. In less quantity of experiment utilize N-acetyl cysteine given that no remarkable enhancement in cases that disorder indication begin into the arms and legs muscle during motor neuron disease.[44] Many neurotropic factors plant in lately estimated in clinically practice. Those composite cover efferent neurons via injury by many steps. Still, at most single elements of insulin, which give rise to useful effects into the decelerating disorder progress.[45]

#### *4.1.2. Some aim to treat your specific symptoms and fewer ends to decelerate development about situation & improve your life period.[9]*

1. Riluzole are selected medicine specially to treat motor neuron disease. Riluzole is used to decelerate the progression of motor neuron disease symptoms. It can increase the life quality of people with motor neuron complaint by 3-6 months.
2. Various health professional specialists must be give remedy for his particular indication.
3. The language & speech remedies may prevent difficulties in swallowing & speech. And physical therapist must be assist among somatic indication such as movement difficulties, muscle spasm and joint stiffness. A physiotherapist can also advise at utilizing outfit around the house and maintaining independence.
4. The nutritionist may give guidance for keep free from illness and nutrition.
5. The drug treatments are also available for muscle spasms and cramps.
6. You might develop swallowing problems that affect your ability to drink and eating safely.
7. You might need to beef through a PEG (percutaneous endoscopic gastrostomy) or a tube in your nose. This a procedure to insert a feeding tube directly in stomach.
8. Whose people which difficulties in breathing might benefit from assisted ventilation and oxygen therapy?

### *4.2. Symptomatic treatment*

According to recent studies, the scene about the part of medicine in dragging survive of motor neuron disease cases as per limited, characteristic remedy have as essential representation into the operation of motor neuron disease. Efficacious operation may also maximize the working,

increase independence and ameliorate status of living. Substantially medicines are useful characteristic to treat grounded on less studies and into another autonomic disease on experiences.

### 4.3. Noninvasive ventilator support

According to recent studies, proceed into remedy of motor neuron disease have describe satisfaction about congenital ventilator keep up, where by motor neuron disease cases used to protection which encoring for less breathing machine, generally at two levels Bipap or BPap (positive airway pressure machine).[46] By wearing a face or nose mask overnight the cases may begin and utilized regularly daytime relaxed his respiration system in the after stages of disease. Noninvasive ventilator support system can relief indication regards to prolonged survival and respiration inadequacy through over to 1 year,[47] additionally for ameliorate quality period of living.[46,48] A pulmonologist also may regulate the cases which acceptable to breathing machine, and proceeds in description elements like disease progression and arms and legs weakness. Cases witness to face symptom like as sialorrhoea and claustrophobia may be assited with the drug of efferent nerves disorder.

**Table 1:** Symptomatic treatment of motor neuron disease[49]

| **Motor dysfunction Symptoms** | **Pharmacological management (treatment)** |
|---|---|
| Dyspnoea | Morphine, Lorazepam |
| Excess saliva | Amitriptyline, atropine |
| Spasticity | Baclofen, clonazepam |
| Cramps/ fasciculation | Carbamazepine, magnesium |
| Thickened saliva | Nebulized mucolytics, normal saline nebulizers |
| Laryngospasm/ paroxysmal choking | Lorazepam, morphine |
| **Non motor dysfunction Symptoms** | **Pharmacological management** |
| Pain | Paracetamol, ibuprofen neuropathic, gabapentin, pregabalin, musculoskeletal |
| Constipation | Aperients, suppositories |
| Sleep disturbance | Amitriptyline, benzodiazepines |
| Emotional lability/depression | Amitriptyline, citalopram, mirtazapine |
| Cognitive dysfunction | Memantine, antidepressant |

### 4.4. Symptomatic treatment

According to recent studies, the scene about the part of medicine in dragging survive of motor neuron disease cases as per limited, characteristic remedy have as essential representation into the operation of motor neuron disease. Efficacious operation may also maximize the working, increase independence and ameliorate status of living. Substantially medicines are useful characteristic to treat

**Table 2:** Diagnosis[50]

| **Symptoms** | **Diagnosis** |
|---|---|
| Structural lesions brain | Cervical spondylotic myelopathy spinal cord tumor/mass/ vascular malformations cervical brain stem tumor/ /mass |
| Degenerative disease | Leukodystrophies (metachromatic leukodystrophy, adreno leukodystrophy, adrenomyeloneuropathy) |
| Neuromuscular disorder | Seronegative myasthenia gravis Polymyositis IBM (Inclusion body myositis) Lambert-Eaton myasthenic syndrome |
| Metabolic nutritional | Hyperthyroidism Vitamin B12 deficiency Copper deficiency Hyperparathyroidism |
| Infection | Human immunodeficiency virus myelopathy |

grounded on less studies and into another autonomic disease on experiences.

### 4.5. Noninvasive ventilator support

According to recent studies, proceed into remedy of motor neuron disease have describe satisfaction about congenital ventilator keep up, where by motor neuron disease cases used to protection which encoring for less breathing machine, generally at two levels Bipap or BPap (positive airway pressure machine).[46] By wearing a face or nose mask overnight the cases may begin and utilized regularly daytime relaxed his respiration system in the after stages of disease. Noninvasive ventilator support system can relief indication regards to prolonged survival and respiration inadequacy through over to 1 year,[47] additionally for ameliorate quality period of living.[46,48] A pulmonologist also may regulate the cases which acceptable to breathing machine, and proceeds in description elements like disease progression and arms and legs weakness. Cases witness to face symptom like as sialorrhoea and claustrophobia may be assited with the drug of efferent nerves disorder.

## 5. Multi Professional Managements

Several correctional awareness that distributed through the relational, psychological, and physical and diapason trust for salutatory motor neuron disease cases. Similar as care generally comprise numerous platoon members, including nanny specialist, physiotherapist, respiratory therapist, neuropsychologist, physical remedies, neurologist & community workers. Numerous study has been show whose cases attend multifunctional awareness which can exist enjoy better & longer aspects of living as comparison that attend only a Multiprofessional clinical.[51] Thses can regards for advanced amount of riluzole medicine utilized

and some sanitarium admission and PEG.

### *5.1. Interpretation*

Efferent nerves disorders are an incorrigible disease; not largely successful remedies are providing on this phase. Characteristics remedy residue through the dependence of operation. The Multiprofessional approach compile in the company of gastrostomy and NIV which may be enhance the extend survival about similar patients & standard period of life. Motor neuron diseases are successfully neuron and muscles disease which origin from the lower & upper efferent neuron loss that shown effected on numerous cases generally death substantially via respiration system block. Sleep disorder breath into motor neuron disease leads to generally precedes habitual respiration system failure and respiratory muscle fault. Those patients which may experiences change sleeping armature, specifically absent reduced rapid eye movement sleeping, periodic branch movements, uneasy, obstructive sleep apnoea and nightly hypoventilation.

## 6. Source of Funding

None.

## 7. Conflicts of interest

There are no conflicts of interest.

## 8. Author's Contributions

Both authors is contributing own precious advice, operation & contribution in collection of accoutrements for this work.

## 9. Acknowledgement

I thankful to Mr. Ravi Kumar for appreciation in this work and support at every critical movement.

## References

1. Allum CW, Shaw PJ. Motor neuron disease: a practical update on diagnosis and management. *Clin Med*. 2010;10(3):252–8.
2. Show P. Motor neurone disease. *BMJ*. 1999;318(7191):1118–21. doi:10.1136/bmj.318.7191.1118.
3. Martin S, Khleifat AA, Al-Chalabi A. What causes amyotrophic lateral sclerosis? *F1000Res*. 2017;6:371. doi:10.12688/f1000research.10476.1.
4. Morozova N, Weisskopf MG, Mccullough ML, Munger KL, Calle EE, Thun MJ, et al. Diet and amyotrophic lateral sclerosis. *Epidemiology*. 2008;19(2):324–37. doi:10.1097/EDE.0b013e3181632c5d.
5. Castanedo VD, Bosque VP, Sainz PA, Riancho J. Infectious agents and amyotrophic lateral sclerosis: Another piece of the puzzle of motor neuron degeneration. *J Neurol*. 2019;266(1):27–36. doi:10.1007/s00415-018-8919-3.
6. Kiernan MC, Talman P, Henderson RD. Establishment of an Australian motor neuron disease registry. *Med J Aust*. 2006;184(7):367–8. doi:10.5694/j.1326-5377.2006.tb00279.x.
7. Kiernan MC, Vucic S, Cheah BC. Amyotrophic lateral sclerosis. *Lancet*. 2011;377(9769):942–55. doi:10.1016/S0140-6736(10)61156-7.
8. Hardiman O, Van Den Berg L, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol*. 2011;7(11):639–49. doi:10.1038/nrneurol.2011.153.
9. Motor Neuron Disease Association, Brain & Spine Foundation. *Registered Charity Number: 1098528 Published: July 2015 Review date*. 2018;.
10. Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. *Neurology*. 2009;72(12):1087–94. doi:10.1212/01.wnl.0000345041.83406.a2.
11. Gordon PH. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. *Aging Dis*. 2013;4(5):295–310. doi:10.14336/AD.2013.0400295.
12. Visser J, de Jong JV, de Visser M. The history of progressive muscular atrophy: syndrome or disease? *Neurology*. 2008;70(9):723–7. doi:10.1212/01.wnl.0000302187.20239.93.
13. Norris FH. Adult spinal motor neuron disease. Progressive muscular atrophy (Aran's disease) in relation to amyotrophic lateral sclerosis. In: Vinken P, Bruyn G, de Jong J, editors. Handbook of Clinical Neurology: System Disorders and Atrophies. Part II. vol. 1975. Amsterdam: North-Holland Publishing Company;. p. 1–56.
14. Praline J, Guennoc AM, Vourc'h P, Toffol BD, Corcia P. Primary lateral sclerosis may occur within familial amyotrophic lateral sclerosis pedigrees. *Amyotroph Lateral Scler*. 2010;11(1-2):154–6.
15. Rosen DR, Siddiqui T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/ Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature*. 1993;362(6415):59–62. doi:10.1038/362059a.
16. Norris F, Shepherd R, Denys E, Mukai E, Elias L, Holden D, et al. Onset, natural history and outcome in idiopathic adult onset motor neuron disease. *J Neurol Sci*. 1993;118(1):48–55. doi:10.1016/0022-510x(93)90245-t.
17. Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. *Neurology*. 2006;66(5):647–53. doi:10.1212/01.wnl.0000200962.94777.71.
18. Ferrante RJ, Brown SE, Shinobu LA, Bowling AC, Baik MJ, Macgarvey U, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. *J Neurochem*. 1997;69(5):2064–74. doi:10.1046/j.1471-4159.1997.69052064.x.
19. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. *Ann Neurol*. 1995;38(4):691–5. doi:10.1002/ana.410380424.
20. Shaw PJ, Chinnery RM, Thagesen H, Borthwick G, Ince PG. Immuno cytochemical study of the distribution of the free radical scavenging enzymes Cu/Zn superoxide dismutase (SOD1), Mn superoxide dismutase (Mn SOD) and catalase in the normal human spinal cord and in motor neurone disease. *J Neurol Sci*. 1997;147(2):115–25. doi:10.1016/s0022-510x(96)05316-6.
21. Aguirre T, Van Den Bosch L, Goetschalckx K, Tilkin P, Mathijis G, Cassiman JJ, et al. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. *Ann Neurol*. 1998;43(4):452–7. doi:10.1002/ana.410430407.
22. Gaig C, Iranzo A. Sleep-disordered breathing in neurodegenerative diseases. *Curr Neurol Neurosci Rep*. 2012;12(2):205–17. doi:10.1007/s11910-011-0248-1.
23. Kimura K, Tachibana N, Kimura J. Sleep-disordered breathing at an early stage of amyotrophic lateral sclerosis. *J Neurol Sci*. 1999;164(1):37–43. doi:10.1016/s0022-510x(99)00044-1.
24. Carratù P, Cassano A, Gadaleta F, Tedone M, Dongiovanni S, Fanfulla F, et al. Association between low sniff nasal-inspiratory pressure (SNIP) and sleep disordered breathing in amyotrophic lateral sclerosis: Preliminary results. *Amyotroph Lateral Scler*. 2011;12(6):458–63. doi:10.3109/17482968.2011.593038.
25. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs. sleep-disordered breathing as predictors of QOL in ALS. *Neurology*. 2001;57(11):2040–4. doi:10.1212/wnl.57.11.2040.
26. Atalaia A, De Carvalho M, Evangelista T, Pinto A. Sleep characteristics of amyotrophic lateral sclerosis in patients with

preserved diaphragmatic function. *Amyotroph Lateral Scler*. 2007;8(2):101–5. doi:10.1080/17482960601029883.
27. Ferguson KA, Strong MJ, Ahmad D. Sleep disordered breathing in amytrophic lateral sclerosis. *Chest*. 1996;110(3):664–9. doi:10.1378/chest.110.3.664.
28. Arnulf I, Similowski T, Salachas F, Mehiri S, Attali V, Behin-Bellhesen V, et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. *Am J Respir Crit Care Med*. 2000;161(3 Pt 1):849–56. doi:10.1164/ajrccm.161.3.9805008.
29. Swash M. Early diagnosis of ALS/MND. *J Neurol Sci*. 1998;160(1):S33–6. doi:10.1016/s0022-510x(98)00215-9.
30. Czaplinski A, Yen AA, Simpson EP, Appel SH. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? *Arch Neurol*. 2006;63(3):1139–43. doi:10.1001/archneur.63.8.1139.
31. Kano OI, Arasaki K, Ikeda K, Iwasaki Y. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis. *Arch Neurol*. 2007;64(3):458–9. doi:10.1001/archneur.64.3.458-b.
32. Audrey MG, Shadfar RS, Vidal M, Jamali MS, Atkin JD. *Front Neurosci*. 2019;13:532. doi:10.3389/fnins.2019.00532.
33. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. *J Neurol*. 1997;244(Suppl 2):3–14. doi:10.1007/BF03160574.
34. Lin CLG, Bristol LA, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter in amyotrophic lateral sclerosis. *Neuron*. 1998;20(3):589–602. doi:10.1016/s0896-6273(00)80997-6.
35. Nagai M, Abe K, Okamoto K, Itoyama Y. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. *Neurosci Lett*. 1998;244(3):165–8. doi:10.1016/s0304-3940(98)00158-x.
36. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. for the Amyotrophic Lateral Sclerosis Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. *Lancet*. 1996;347(9013):1425–31. doi:10.1016/s0140-6736(96)91680-3.
37. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. *Neurology*. 1998;50(1):66–72. doi:10.1212/wnl.50.1.66.
38. Desport JC, Preux PM, Truong TC. Nutritional status is a prognostic factor for survival in ALS patients. *Neurology*. 1999;53(5):1059–63. doi:10.1212/wnl.53.5.1059.
39. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with ALS: relation of the proximity of death. *Am J Clin Nutr*. 1996;63(1):130–7. doi:10.1093/ajcn/63.1.130.
40. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrère B, et al. Factors correlated with hyper metabolism in patients with amyotrophic lateral sclerosis. *Am J Clin Nutr*. 2001;74(3):328–34. doi:10.1093/ajcn/74.3.328.
41. Worwood A, Leigh PN. Indicators and prevalence of malnutrition in MND. *Eur Neurol*. 1998;40(3):159–63. doi:10.1159/000007973.
42. Silani V, Kasarskis EJ, Yanagisawa N. Nutritional management in ALS: A worldwide perspective. *J Neurol*. 1998;245(Suppl 2):13–9.
43. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. *Lancet*. 1996;347(9013):1425–31. doi:10.1016/s0140-6736(96)91680-3.
44. Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FP, De Jong J. Randomized, double-blind controlled trial of acetylcysteine in amyotrophic lateral sclerosis. *Arch Neurol*. 1995;52(6):559–64. doi:10.1001/archneur.1995.00540300031009.
45. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-1 on progression in ALS. *Neurology*. 1997;49(6):1621–30. doi:10.1212/wnl.49.6.1621.
46. Mcdermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. *BMJ*. 2008;336(7645):658–62. doi:10.1136/bmj.39493.511759.BE.
47. Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory aids. *Chest*. 2002;122(1):92–8. doi:10.1378/chest.122.1.92.
48. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. *Lancet Neurol*. 2006;5(2):140–7. doi:10.1016/S1474-4422(05)70326-4.
49. Dharmadasa T, Henderson RD, Talman PS, Macdonell RAL, Mathers S, Schultz DW, et al. Motor neurone disease: progress and challenges. *MJA*. 2017;206(8).
50. Lee CN. Reviewing evidences on the management of patients with motor neuron disease. *Hong Kong Med J*. 2012;18(1):48–55.
51. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study. *J Neurol Neurosurg Psychiatry*. 1996;74(9):1258–61. doi:10.1136/jnnp.74.9.1258.

## Author biography

**Gautam Kumar,** Student

**Ravi Kumar,** Assistant Professor

**Kuldeep Saini,** Assistant Professor

**Sunita Jha,** Assistant Professor

**Cite this article:** Kumar G, Kumar R, Saini K, Jha S. Management of motor neuron disease with updated therapies: A review. *IP Indian J Neurosci* 2023;9(1):1-7.